714 related articles for article (PubMed ID: 31464120)
1. Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study.
Matsumura A; Miyazaki T; Tachibana T; Ando T; Koyama M; Koyama S; Ishii Y; Takahashi H; Nakajima Y; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S; Nakajima H
Turk J Haematol; 2020 Feb; 37(1):20-29. PubMed ID: 31464120
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide.
Greco R; Lorentino F; Nitti R; Lupo Stanghellini MT; Giglio F; Clerici D; Xue E; Lazzari L; Piemontese S; Mastaglio S; Assanelli A; Marktel S; Corti C; Bernardi M; Ciceri F; Peccatori J
Front Immunol; 2019; 10():2319. PubMed ID: 31632401
[No Abstract] [Full Text] [Related]
3. Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Aladağ Karakulak E; Demİroğlu H; Malkan UY; Akman U; Göker H; Büyükaşik Y
Turk J Med Sci; 2021 Feb; 51(1):355-358. PubMed ID: 32927932
[TBL] [Abstract][Full Text] [Related]
4. ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide.
Solán L; Kwon M; Carbonell D; Dorado N; Balsalobre P; Serrano D; Chicano-Lavilla M; Anguita J; Gayoso J; Díez-Martín JL; Martínez-Laperche C; Buño I
Front Immunol; 2019; 10():2338. PubMed ID: 31649665
[TBL] [Abstract][Full Text] [Related]
5. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
[TBL] [Abstract][Full Text] [Related]
6. Soluble interleukin-2 receptor index predicts the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.
Nakamura Y; Tanaka Y; Tanaka M; Sugiyama A; Yamamoto K; Tokunaga Y; Yujiri T; Tanizawa Y
Int J Hematol; 2016 Apr; 103(4):436-43. PubMed ID: 26791380
[TBL] [Abstract][Full Text] [Related]
7. Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation.
Gjaerde LK; Ostrowski SR; Minculescu L; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Eur J Haematol; 2021 Mar; 106(3):417-424. PubMed ID: 33314420
[TBL] [Abstract][Full Text] [Related]
8. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
[TBL] [Abstract][Full Text] [Related]
9. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
10. Level of vascular endothelial growth factor predicts both relapse and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
Moiseev IS; Lapin SV; Surkova EA; Lerner MY; Vavilov VN; Afanasyev BV
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1677-82. PubMed ID: 24035780
[TBL] [Abstract][Full Text] [Related]
11. Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant.
Nakane T; Fukuda T; Kanda J; Taniguchi S; Eto T; Ohashi K; Nakamae H; Kurokawa M; Mori T; Morishima Y; Nagamura-Inoue T; Sakamaki H; Atsuta Y; Murata M
Leuk Lymphoma; 2015; 56(8):2392-7. PubMed ID: 25629984
[TBL] [Abstract][Full Text] [Related]
12. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease.
Großekatthöfer M; Güclü ED; Lawitschka A; Matthes-Martin S; Mann G; Minkov M; Peters C; Seidel MG
Ann Hematol; 2013 Aug; 92(8):1121-8. PubMed ID: 23604429
[TBL] [Abstract][Full Text] [Related]
13. Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation.
Modi A; Rybicki L; Majhail NS; Mossad SB
Transpl Infect Dis; 2020 Feb; 22(1):e13217. PubMed ID: 31769584
[TBL] [Abstract][Full Text] [Related]
14. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.
Vander Lugt MT; Braun TM; Hanash S; Ritz J; Ho VT; Antin JH; Zhang Q; Wong CH; Wang H; Chin A; Gomez A; Harris AC; Levine JE; Choi SW; Couriel D; Reddy P; Ferrara JL; Paczesny S
N Engl J Med; 2013 Aug; 369(6):529-39. PubMed ID: 23924003
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of intestinal graft-versus-host disease and thrombotic microangiopathy after allogeneic stem cell transplantation.
Yamada-Fujiwara M; Miyamura K; Fujiwara T; Tohmiya Y; Endo K; Onishi Y; Ishizawa K; Kameoka J; Ito M; Harigae H
Tohoku J Exp Med; 2012 May; 227(1):31-7. PubMed ID: 22531159
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling.
Johnpulle RA; Paczesny S; Jung DK; Daguindau E; Jagasia MH; Savani BN; Chinratanalab W; Cornell RF; Goodman S; Greer JP; Kassim AA; Sengsayadeth S; Byrne MT; Engelhardt BG
Biol Blood Marrow Transplant; 2017 Mar; 23(3):529-532. PubMed ID: 28013014
[TBL] [Abstract][Full Text] [Related]
17. Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Gatza E; Braun T; Levine JE; Ferrara JL; Zhao S; Wang T; Chang L; Harris A; Pawarode A; Kitko C; Magenau JM; Yanik GA; Couriel DR; Goldstein S; Connelly J; Reddy P; Paczesny S; Choi SW
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1426-34. PubMed ID: 24892263
[TBL] [Abstract][Full Text] [Related]
18. Multiple functional variants in the
Karaesmen E; Hahn T; Dile AJ; Rizvi AA; Wang J; Wang T; Haagenson MD; Preus L; Zhu Q; Liu Q; Yan L; Liu S; Haiman CA; Stram D; Pooler L; Sheng X; Van Den Berg D; Brock G; Webb A; McCarthy PL; Pasquini MC; Spellman SR; Lee SJ; Paczesny S; Sucheston-Campbell LE
Blood Adv; 2019 Aug; 3(16):2512-2524. PubMed ID: 31455667
[TBL] [Abstract][Full Text] [Related]
19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
Kimura SI; Tamaki M; Okinaka K; Seo S; Uchida N; Igarashi A; Ozawa Y; Ikegame K; Eto T; Tanaka M; Shiratori S; Nakamae H; Sawa M; Kawakita T; Onizuka M; Fukuda T; Atsuta Y; Kanda Y; Nakasone H
Ann Hematol; 2021 Dec; 100(12):3029-3038. PubMed ID: 34490500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
